Jincong Q. Freeman

Chicago Department of Public Health — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index338citations115works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(29), Global Cancer Incidence and Screening(16), Cancer survivorship and care(14), BRCA gene mutations in cancer(12), COVID-19 and healthcare impacts(11)

Publications115 total

Abstract PD1-02: Racial and Socioeconomic Disparities in Patterns of Metastatic Disease Presentation and Treatment Among Patients With de novo Metastatic HR-Positive, HER2-Negative Breast Cancer
Clinical Cancer Research·2026
Trends in Nonsurgical Management for Low-Risk, Hormone Receptor–Positive Ductal Carcinoma In Situ
JAMA Network Open·2026Open Access
Adjuvant Chemotherapy Use for Hormone Receptor–Positive, <i>ERBB2</i> -Negative Breast Cancer After RxPONDER Trial
JAMA Network Open·2025· 2 citedOpen Access
Skin Cancer Predisposition Genes, Full‐Body Skin Examinations, Familial Disclosure, and Genetic Testing Among High‐Risk Individuals
International Journal of Dermatology·2025Open Access
Racial and ethnic disparities and socioeconomic determinants of male breast cancer mortality in the United States
Breast Cancer Research and Treatment·2025· 1 citedOpen Access
CATCHING CACHE VALLEY VIRUS: IMMUNODEFICIENCY AND IKAROS VARIANTS
Annals of Allergy Asthma & Immunology·2025
Awareness, knowledge, and attitudes toward polygenic risk scores for breast cancer in multiethnic high-risk cohorts of women
Genetics in Medicine·2025
Factors Associated With Fear of Cancer Recurrence in a Multiethnic Cohort of Patients With Breast Cancer
Psycho-Oncology·2025Open Access
Telehealth utilization and cancer genetic testing discussion and uptake in US adults.
JCO Oncology Practice·2025· 1 cited
Temporal trends in active surveillance and treatment strategies for low-risk, hormone receptor-positive ductal carcinoma in situ in the US.
JCO Oncology Practice·2025
Vision impairment and service utilization among cancer survivors and the general population in the US.
JCO Oncology Practice·2025
Discussion and uptake of cancer genetic testing among sexual minorities in the US adult population.
JCO Oncology Practice·2025
Factors associated with fear of cancer recurrence in a multiethnic cohort of patients with breast cancer.
JCO Oncology Practice·2025
Gaps in perceived climate change harm on health among cancer survivors and the US general population.
JCO Oncology Practice·2025
Abstract B082: Exploring climate change harm perception and associated racial/ethnic gaps in US cancer survivors
Cancer Epidemiology Biomarkers & Prevention·2025
Abstract C067: Race and age-related differences in adjuvant chemotherapy use for hormone receptor-positive/HER2-negative breast cancer by genomic risk
Cancer Epidemiology Biomarkers & Prevention·2025
Abstract A102: Association between neighborhood-level socioeconomic deprivation and colon cancer recurrence following colectomy: A retrospective study
Cancer Epidemiology Biomarkers & Prevention·2025
Abstract A133: Assessing functional disability status across sexual orientations among cancer survivors in the US
Cancer Epidemiology Biomarkers & Prevention·2025
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer
Annals of Oncology·2025· 1 citedOpen Access
Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer
Journal of Clinical Oncology·2025· 2 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Dezheng Huo(17), Rita Nanda(16), Frederick M. Howard(13), Fangyuan Zhao(10), Olufunmilayo I. Olopade(10), Olasubomi J. Omoleye(7), Ted Akhiwu(7), Dezheng Huo(6), Sudha Yarlagadda(6), Poornima Saha(6), Sarah P. Shubeck(5), James Li(5), Gini F. Fleming(5), Amy R. Baugher(4), Kent Schechter(4), Jared H. Hara(4), Cyprian Wejnert(3), Nataly Montano Vargas(3), Yan Ma(3), Andrew C. Meltzer(3)